Zealand Pharma A/S
CSE:ZEAL
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
315.4
954
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Zealand Pharma A/S
Zealand Pharma A/S
Other Current Liabilities
Zealand Pharma A/S
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Other Current Liabilities
kr4.3B
|
CAGR 3-Years
49%
|
CAGR 5-Years
54%
|
CAGR 10-Years
18%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Other Current Liabilities
€298.3m
|
CAGR 3-Years
150%
|
CAGR 5-Years
54%
|
CAGR 10-Years
37%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Other Current Liabilities
kr2B
|
CAGR 3-Years
193%
|
CAGR 5-Years
165%
|
CAGR 10-Years
30%
|
|
|
F
|
Fluoguide AS
STO:FLUO
|
Other Current Liabilities
kr2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
104%
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Other Current Liabilities
kr80k
|
CAGR 3-Years
-84%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
-37%
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a dynamic biotechnology company based in Denmark, on a mission to create innovative peptide-based therapeutics that address unmet medical needs, particularly in the fields of diabetes, obesity, and gastrointestinal disorders. Founded in 1999, Zealand's commitment to research excellence has positioned it at the forefront of peptide drug discovery and development. Its proprietary pipeline includes promising candidates such as dasiglucagon, an ultra-rapid treatment for diabetes, and ezotic for obesity management, illustrating the company's focus on high-impact therapeutic solutions that aim to improve the quality of life for patients worldwide. As an investor, understanding Zealand's strategic partnerships and collaborations with major pharmaceutical organizations underscores its ability to leverage expertise and resources, thereby accelerating the development of its product offerings. With a strong foundation built on scientific innovation, Zealand Pharma has garnered significant attention from the investment community, reflecting its robust growth potential. The company’s publicly traded status on NASDAQ Copenhagen allows investors to participate in its journey as it aims for regulatory approvals and commercialization of its lead candidates. Zealand's agile approach to the ever-evolving landscape of biotechnology, combined with a commitment to sustainable practices, positions it as a forward-thinking player in the industry. Thus, for investors, Zealand Pharma presents a compelling opportunity within the healthcare sector, where advancements in biopharma are increasingly critical in addressing global health challenges.
You don't have any saved screeners yet
